ImmunoGen (IMGN) Receives Daily News Impact Rating of 0.21
Media coverage about ImmunoGen (NASDAQ:IMGN) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmunoGen earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.70987413467 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Brokerages Expect ImmunoGen, Inc. (NASDAQ:IMGN) to Announce -$0.27 EPS (americanbankingnews.com)
- ImmunoGen, Inc. (IMGN) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- ImmunoGen, Inc. (IMGN) vs. Celldex Therapeutics, Inc. (CLDX): Breaking Down the Biotechnology Industry’s Two … – StockNewsGazette (stocknewsgazette.com)
- Jazz Pharmaceuticals : Technical Snapshots for These Biotech Stocks — ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma (4-traders.com)
- Consensus score reveals Buy position in Stock: Nabors Industries Ltd. (NBR) (fishinghd.com)
A number of research firms have issued reports on IMGN. Zacks Investment Research cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Royal Bank Of Canada upgraded shares of ImmunoGen from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $5.00 to $12.00 in a research note on Thursday, July 6th. Cantor Fitzgerald set a $5.00 target price on shares of ImmunoGen and gave the company a “hold” rating in a research note on Friday, July 28th. Jefferies Group LLC reiterated a “buy” rating and issued a $6.00 target price on shares of ImmunoGen in a research note on Wednesday, June 28th. Finally, William Blair reiterated an “outperform” rating on shares of ImmunoGen in a research note on Monday, June 26th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.72.
Shares of ImmunoGen (IMGN) traded up 5.54% during mid-day trading on Friday, hitting $5.72. 3,360,937 shares of the stock were exchanged. The firm has a 50-day moving average price of $6.40 and a 200 day moving average price of $4.41. ImmunoGen has a 12-month low of $1.51 and a 12-month high of $8.04. The company’s market capitalization is $512.50 million.
ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to analyst estimates of $30.59 million. During the same period in the prior year, the business earned ($0.53) EPS. The company’s revenue for the quarter was up 426.6% compared to the same quarter last year. On average, equities research analysts expect that ImmunoGen will post ($0.84) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “ImmunoGen (IMGN) Receives Daily News Impact Rating of 0.21” was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/13/immunogen-imgn-receives-daily-news-impact-rating-of-0-21.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.